Aletaha D, Funovits J, Ward M M, Smolen J S, Kvien T K
Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria.
Arthritis Rheum. 2009 Mar 15;61(3):313-20. doi: 10.1002/art.24282.
To analyze the minimum clinically important improvement (MCII) of disease activity measures in rheumatoid arthritis (RA) using patient-derived anchors, and to assess whether criteria for improvement differ with baseline disease activity.
We used data from a Norwegian observational database comprising 1,050 patients (73% women, 65% rheumatoid factor-positive, mean duration of RA 7.7 years). At 3 months after initiation of therapy, patients indicated whether their condition had improved, had considerably improved, was unchanged, had worsened, or had considerably worsened. We used receiver operating characteristic curve analysis to determine the MCII for the Disease Activity Score based on the assessment of 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), and the Clinical Disease Activity Index (CDAI), and analyzed the effects of different levels of baseline disease activity on the MCII.
On average, patients started with high disease activity and improved significantly during treatment (American College of Rheumatology 20%, 50%, and 70% improvement criteria responses were 37%, 17%, and 5%, respectively). The overall mean (95% confidence interval [95% CI]) thresholds for MCII after 3 months for the DAS28, SDAI, and CDAI were 1.20 (95% CI 1.18-1.22), 10.95 (95% CI 10.69-11.20), and 10.76 (95% CI 10.49-11.04), respectively, and the mean (95% CI) thresholds for major responses were 1.82 (95% CI 1.80-1.83), 15.82 (95% CI 15.65-16.00), and 15.00 (95% CI 14.82-15.18), respectively. With increasing disease activity, much higher changes in disease activity were needed to achieve MCII according to patient judgment.
The perception of improvement of disease activity of patients with RA is considerably different depending on the disease activity level at which they start.
使用患者来源的锚定指标分析类风湿关节炎(RA)疾病活动度测量的最小临床重要改善(MCII),并评估改善标准是否因基线疾病活动度而异。
我们使用了来自挪威一个观察性数据库的数据,该数据库包含1050名患者(73%为女性,65%类风湿因子阳性,RA平均病程7.7年)。在开始治疗3个月后,患者指出他们的病情是有所改善、显著改善、未改变、恶化还是显著恶化。我们使用受试者工作特征曲线分析来确定基于28个关节评估的疾病活动评分(DAS28)、简化疾病活动指数(SDAI)和临床疾病活动指数(CDAI)的MCII,并分析不同水平的基线疾病活动度对MCII的影响。
平均而言,患者开始时疾病活动度较高,治疗期间显著改善(美国风湿病学会20%、50%和70%改善标准的应答率分别为37%、17%和5%)。DAS28、SDAI和CDAI在3个月后的MCII总体平均(95%置信区间[95%CI])阈值分别为1.20(95%CI 1.18 - 1.22)、10.95(95%CI 10.69 - 11.20)和10.76(95%CI 10.49 - 11.04),主要应答的平均(95%CI)阈值分别为1.82(95%CI 1.80 - 1.83)、15.82(95%CI 15.65 - 16.00)和15.00(95%CI 14.82 - 15.18)。随着疾病活动度增加,根据患者判断,要实现MCII需要疾病活动度有更高的变化。
RA患者对疾病活动度改善的感知因起始疾病活动度水平的不同而有很大差异。